Subscribe
jarun-ontakrai
Jarun Ontakrai/ Shutterstock.com
14 May 2020Big Pharma

Natera and Illumina settle litigation, agree mutual licence

Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Natera accuses CareDx of infringing DNA testing patents
17 May 2022   Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Big Pharma
Invitae claims Natera infringed DNA patents
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Americas
Illumina to acquire Jeff Bezos-backed cancer testing company
23 September 2020   Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Natera accuses CareDx of infringing DNA testing patents
17 May 2022   Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Big Pharma
Invitae claims Natera infringed DNA patents
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Americas
Illumina to acquire Jeff Bezos-backed cancer testing company
23 September 2020   Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.

More on this story

Big Pharma
Natera accuses CareDx of infringing DNA testing patents
17 May 2022   Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Big Pharma
Invitae claims Natera infringed DNA patents
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Americas
Illumina to acquire Jeff Bezos-backed cancer testing company
23 September 2020   Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB